Interview with Dr. William Carter, CEO of Hemispherx Biopharma |
 |
 |
| By M.E.Garza | |
| Friday, 09 October 2009 03:00 | |
|
During the interview, there are references made to various materials which can be found/downloaded/seen via the links on the right.
Disclosure: No Positions
BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
An interview with Dr. William Carter, CEO of Hemispherx Biopharma (AMEX:HEB) regarding the status of the NDA for Ampligen as a first line treatment for Chronic Fatigue Syndrome as well as his company's pipeline plans for Alferon LDO (Low Dose Oral) application.
about 8 hours ago
Watson Provides Update on Generic Lidoderm® Application; Gilead Soars On "Striking" Clinical Trial Data: Below i... http://t.co/IbLYNqgb
about 16 hours ago
Shares of $IDIX drop slightly after compelling new data from rival Gilead ($GILD) puts prospects for IDIX's hepatitis C drug in question.
about 1 day ago
Medgenics has Key to Protein Therapy Market: Medgenics (NASDAQ: MDGN) has what I believe to be the most disrupti... http://t.co/c3IBIWYR
about 1 day ago
Stocks Vacillate To Mixed Finish; Some Leaders Rally http://t.co/dtOQTRgh
about 1 day ago
Myriad's Prolaris Test Shown to Significantly Predict Biochemical Recurrence Risk; FDA Approves JANUMET XR: Belo... http://t.co/a7IlIvbS
about 1 day ago
Athersys $ATHX gets grant to study traumatic brain injury http://t.co/mnZTsxXx
about 1 day ago
Watching: San Antonio patients help test new 'spray-on skin' for burns http://t.co/fzKA9B23
about 1 day ago
OncoSec's President and CEO explains his firm's ambitious list of milestones for 2012: During the past few sessi... http://t.co/fKOMc1TM
Free Phone Trade Alerts
